Αποτελέσματα αναζήτησης - "неклапанная фибрилляция предсердий"

1

Report

ОткРытое наблюдательное Исследование динамики изменения КОгнитивных функций у пациентов, перенесших иШЕмический инсульт на фоне неклапанной фибрилляции предсердий с последующим стартом Терапии ривароксабаном (РИКОШЕТ)

Θεματικοί όροι: ишемический инсульт, неклапанная фибрилляция предсердий, ривароксабан, когнитивные нарушения, ischemic stroke, nonvalvular atrial fibrillation, cognitive impairment, rivaroxaban

2

Academic Journal

Left Atrial Thrombosis before Catheter Ablation or Cardioversion in Patients with Non-valvular Atrial Fibrillation or Atrial Flutter: what Risk Score is Most Informative? ; Тромбоз левого предсердия и его ушка перед катетерной аблацией или кардиоверсией у больных с неклапанной фибрилляцией или трепетанием предсердий: какая шкала оценки риска наиболее информативна?

Συγγραφείς: I. A. Zaigraev, I. S. Yavelov, O. M. Drapkina, E. V. Bazaeva, И. А. Заиграев, И. С. Явелов, О. М. Драпкина, Е. В. Базаева

Συνεισφορές: Исследование проведено при поддержке Национального медицинского исследовательского центра терапии и профилактической медицины.

Πηγή: Rational Pharmacotherapy in Cardiology; Vol 19, No 2 (2023); 117-125 ; Рациональная Фармакотерапия в Кардиологии; Vol 19, No 2 (2023); 117-125 ; 2225-3653 ; 1819-6446

Θεματικοί όροι: кардиоверсия, non-valvular atrial fibrillation, left atrial thrombosis, left atrial appendage thrombosis, risk score, СHA2DS2-VASc-RAF, catheter ablation, cardioversion, неклапанная фибрилляция предсердий, тромбоз левого предсердия, тромбоз ушка левого предсердия, шкала оценки риска, CHA2DS2-VASc-RAF, катетерная аблация

Περιγραφή αρχείου: application/pdf

Relation: https://www.rpcardio.com/jour/article/view/2871/2408; https://www.rpcardio.com/jour/article/downloadSuppFile/2871/813; https://www.rpcardio.com/jour/article/downloadSuppFile/2871/814; Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J. 2021;42(5):373-498. DOI:10.1093/eurheartj/ehaa612.; January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2019;74(1):104-32. DOI:10.1016/j.jacc.2019.01.011.; Beigel R, Wunderlich NC, Ho SY, et. al. The Left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7(12):1251-65. DOI:10.1016/j.jcmg.2014.08.009.; Scherr D, Dalal D, Chilukuri K, et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation 2009. J Cardiovasc Electrophysiol. 2009;20(4):379-84. DOI:10.1111/j.1540-8167.2008.01336.x.; Li G, Lip GYH, Holbrook A, et al. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies. Eur J Epidemiol. 2019;34(2):173-90. DOI:10.1007/s10654-018-0415-7.; Almutairi AR, Zhou L, Gellad WF, et al. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Metaanalyses. Clin Ther. 2017;39(7):1456-78. DOI:10.1016/j.clinthera.2017.05.358.; Li W, Gao R, Zhao J, et al. Safety and efficacy of different anticoagulation regimens after left atrial appendage occlusion. Ann Palliat Med. 2022;11(1);201-9. DOI:10.21037/apm-21-3654.; Lurie A, Wang J, Hinnegan KJ, et al. Prevalence of left atrial thrombus in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2021;77(23):2875-86. DOI:10.1016/j.jacc.2021.04.036.; Romero J, Cao JJ, Garcia MJ, et. al. Cardiac imaging for assessment of left atrial appendage stasis and thrombosis. Nat Rev Cardiol. 2014;11(8):470-80. DOI:10.1038/nrcardio.2014.77.; Hwang JJ, Chen JJ, Lin SC, et аl. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol. 1993;72(9):677-81. DOI:10.1016/0002-9149(93)90884-f.; Doukky R, Khandelwal A, Garcia-Sayan E, et al. External validation of a novel transthoracic echocardiographic tool in predicting left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013;14(9):876-81. DOI:10.1093/ehjci/jes313.; Chen Y, Liu Q, Liu L, et al. Effect of metabolic syndrome on risk stratification for left atrial or left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Chin Med J (Engl). 2016;129(20):2395-402. DOI:10.4103/0366-6999.191744.; Sikorska A, Baran J, Pilichowska-Paszkiet E, et al. Risk of left atrial appendage thrombus in patients scheduled for ablation for atrial fibrillation: beyond the CHA2DS2VASc score. Pol Arch Med Wewn. 2015;125(12):921-8. DOI:10.20452/pamw.3213.; Kapłon-Cieślicka A, Budnik M, Gawałko M, et al. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. Heart. 2019;105(17):1310-5. DOI:10.1136/heartjnl2018-314492.; Aspberg S, Chang Y, Atterman A, et al. Comparison of the ATRIA, CHADS2, and CHA2DS2-VASc stroke risk scores in predicting ischaemic stroke in a large Swedish cohort of patients with atrial fibrillation. Eur Heart J. 2016; 37(42):3203-10. DOI:10.1093/eurheartj/ehw077.; Piccini JP, Stevens SR, Chang Y, et al. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R2CHADS2 index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts. Circulation. 2013;127(2):224-32. DOI:10.1161/CIRCULATIONAHA.112.107128.; Kiliszek M, Szpakowicz A, Filipiak KJ, et al. CHA2DS2-VASc and R2CHA2DS2-VASc scores have predictive value in patients with acute coronary syndromes. Pol Arch Med Wewn. 2015;125 (7-8):545-52. DOI:10.20452/pamw.2965.; Chao TF, Lip GY, Liu CJ, et al. Validation of Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nation wide Cohort Study. Stroke. 2016;47(10):2462-9. DOI:10.1161/STROKEAHA.116.013880.; Barra S, Almeida I, Caetano F, et al. Stroke prediction with an adjusted R-CHA2DS2VASc score in a cohort of patients with a Myocardial Infarction. Thromb Res. 2013;132(2):293-9. DOI:10.1016/j.thromres.2013.06.025.; Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158(11):825-30. DOI:10.7326/0003-4819-158-11-201306040-00007.; Huang J, Wu SL, Xue YM, et al. Association of CHADS2 and CHA2DS2-VASc Scores with Left Atrial Thrombus with Nonvalvular Atrial Fibrillation: A Single Center Based Retrospective Study in a Cohort of 2695 Chinese Subject. Biomed Res Int. 2017;2017:6839589. DOI:10.1155/2017/6839589.; Yumei X, Jun H, Shulin W. GW24-e3109 correlation of CHADS2 and CHA2DS2-VASc scores with left atrial thrombus in Chinese patients with nonvalvular atrial fibrillation. Heart. 2013;99:A186. DOI:10.1136/heartjnl-2013-304613.519.; Заиграев И. А., Явелов И. С., Драпкина О. М., Базаева Е. В. Предикторы тромбоза левого предсердия и его ушка перед катерной аблацией или кардиоверсией у больных с неклапанной фибрилляцией или трепетанием предсердий. Кардиоваскулярная Терапия и Профилактика. 2022;21(12):3443. DOI:10.15829/1728-8800-2022-3443.; https://www.rpcardio.com/jour/article/view/2871

Διαθεσιμότητα: https://www.rpcardio.com/jour/article/view/2871
https://doi.org/10.20996/1819-6446-2023-03-04

View record from BASE

3

Academic Journal

Thrombus of left atrium and/or its appendage in nonvalvular atrial fibrillation: echocardiographic and laboratory risk factors, capabilities for prediction and correction ; Тромбоз левого предсердия и/или его ушка при неклапанной фибрилляции предсердий: эхокардиографические и лабораторные факторы риска, возможности прогнозирования и коррекции

Συγγραφείς: I. A. Zaigraev, I. S. Yavelov, И. А. Заиграев, И. С. Явелов

Πηγή: Aterotromboz = Atherothrombosis; № 1 (2020); 56-70 ; Атеротромбоз; № 1 (2020); 56-70 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2017-3

Θεματικοί όροι: предикторы, non-valvular atrial fibrillation, left atrium, left atrial appendage, thrombosis, risk factors, predictors, неклапанная фибрилляция предсердий, левое предсердие, ушко левого предсердия, тромбоз, факторы риска

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/214/239; January C.T., Wann L.S., Alpert J.S., Calkins H., Cigarroa J.E., Cleveland J.C. Jr. et aL 2014 AHA/ ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation. 2014;130(23):2071-2104. doi:10.1161/CIR.0000000000000040.; Scherr D., Dalai D., ChiLukuri K., Dong J., Spragg D., Henrikson C.A. et aL. Incidence and predictors of Left atriaL thrombus prior to catheter abLation of atrial fibrillation 2009. J Cardiovasc Electrophysiol. 2009;20(4):379-384. doi:10.1111/j.1540-8167.2008.01336.x.; Kirchhof P., Benussi S., Kotecha D., AhLsson A., Atar D., Casadei B. et aL. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962. doi:10.1093/eurheartj/ehw210.; Beigel R., Wunderlich N.C., Ho S.Y, Arsanjani R., Siegel R.J. The Left atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7(12):1251-1265. doi:10.1016/j.jcmg.2014.08.009.; Frenkel D., D'Amato S.A., Markowitz S.M., Liu C.F., Thomas G., Ip J.E. et al. Prevalence ofleft atrial thrombus detection by transesophageal echocardiography a comparison of continuous non-vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC Clin Electrophysiol. 2016;2(3):295-303. doi:10.1016/j.jacep.2016.01.004.; Stoddard M.F., Singh P., Buddhadeb D., Longaker R. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003;145(4):676-682. doi:10.1067/mhj.2003.91.; Doukky R., KhandeLwaL A., Garcia-Sayan E. External vaHdation of a novel transthoracic echocardiographic tool in predictingLeft atrial appendage thrombus formation in patients with nonvalvular atrial fibriUation. Eur Heart J Cardiovasc Imaging. 2013;14(9):876-881. doi:10.1093/ehjci/jes313.; Kawabata M., Goya M., Sasaki T., Maeda S., Shirai Y., Yoshitake T. et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial Н^^^п patients during anticoaguLation therapy - Warfarin vs. Direct Oral Anticoagulants. Circ J. 2017;81(5):645-651. doi:10.1253/circj.CJ-16-1089.; Blustin J.M., McBane R.D., Mazur M., Ammash N., Sochor O., GriU D.E., Wysokinski W.E. The association between thromboembolic complications and blood group in patients with atrial fibriUation. Mayo Clin Proc. 2015;90(2):216-223. doi:10.1016/j.mayocp.2014.11.013.; Заиграев И.А., Явелов И.С. Тромбоз левого предсердия и/или его ушка при неклапанной фибрилляции предсердий: частота выявления и клинические факторы риска. Атеротромбоз. 2019(2):68-79. doi:10.21518/2307-1109-2019-2-68-79.; Jenkins P.V., O'Donnell J.S. ABO blood group determines plasma von Willebrand factorlev-els: a biologic function after all? Transfusion. 2006;46(10):1836-1844. doi:10.1111/j.1537-2995.2006.00 975.x.; Guo Y., Lip G.Y.H., Apostolakis S. Inflammatory Biomarkers and Atrial Fibrillation: Potential Role of Inflammatory Pathways in the Pathogenesis of Atrial Fibrillation-induced Thromboembolism. Curr Vasc Pharmacol. 2015;13(2):192-201. doi:10.2174/15701611113116660165.; Meus R., Son M., Sobczyk D. Prothrombotic state in patients with aleft atrial appendage thrombus of unknown origin and cerebrovascular events. Stroke. 2016;47(7):1872-1878. doi:10.1161/STROKEAHA.116.012856.; Yuan Fu, Kuibao Li, Xinchun Yang. ABO blood groups: a risk factor forleft atrial andleft atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation. Thromb Res. 2017;156:45-50. doi:10.1016/j.thromres.2017.05.018.; Kaya A., Tukkan C., Alper A.T., Gungor B., Ozcan K.S., Tatlisu M.A. et al. Increasedlevels of red cell distribution width is correlated with presence ofleft atrial stasis in patients with non-valvular atrial fibrillation. North Clin Istanb. 2017;4(1):66-72. doi:10.14744/nci.2017.72324.; Lappe J.M., Horne B.D., Shah S.H., May H.T., Muhlestein J.B., Lappe D.L. et al. Red cell distribution width, C-reactive protein, the complete blood count, and mortality in patients with coronary disease and a normal comparison population. Clin Chim Acta. 2011;412(23-24):2094-2099. doi:10.1016/j.cca.2011.07.018.; Providencia R., Ferreira M.J., Gonsalves L., Paiva L., Fernandes A., Barra S. et al. Mean corpuscular volume and red cell distribution width as predictors of left atrial stasis in patients with non-valvular atrial fibrillation. Am J Cardiovasc Dis. 2013;3(2):91-102. Available at: https://europepmc.org/article/pmc/pmc3683407#abstract; Ulu S.M., Ozkeqeci G., Akci O., Ahsen A., Altug A., Demir K., Acarturk G. Mean platelet volume, in predicting severity of mitral regurgitation and left atrial appendage thrombosis. Blood Coagul Fibrinolysis. 2014;25(2):119-124. doi:10.1097/MBC.0b013e328364c453.; Hong-ling Yang, Yong-Ping Lin, Yan Long, Qing-ling Ma, Cheng Zhou. Predicting cardioembolic stroke with the B-type natriuretic peptide test: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2014;23(7):1882—1889. doi:10.1016/j.jstrokecere-brovasdis.2014.02.014.; Pant R., Patel M., Garcia-Sayan E., Wassouf M., D'Silva O., Kehoe R.F., Doukky R. Impact of B-type natriuretic peptidelevel on the risk ofleft atrial appendage thrombus in patients with nonvalvular atrial fibrillation: a prospective study. Cardiovasc Ultrasound. 2015;14:4. doi:10.1186/s12947-016-0047-6.; Doukky R., Gage H., Nagarajan V., Demopoulos A., Cena M., Garcia-Sayan E. et al. B-type natriuretic peptide predictsleft atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Echocardiography. 2013;30(8):889-895. doi:10.1111/echo.12169.; Ochiumi Y., Kagawa E., Kato M., Sasaki S., Nakano Y., Itakura K. et al. Usefulness of brain natriuretic peptide for predictingleft atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation. J Arrhythm. 2015;31:307-312. doi:10.1016/j.joa.2015.04.002.; Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American society of echocardiography and the European association of cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2016;17(4):412. doi:10.1093/ehjci/jew041.; Mancia G., Fagard R., Narkiewicz K., Redan J., Zanchetti A., Bohm M. et al. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens. 2013;31(10):1925-1238. doi:10.1097/HJH.0b013e328364ca4c.; Boyd A.C., McKay T., Nasibi S., Richards D.A.B., Thomas L. Left ventricular mass predictsleft atrial appendage thrombus in persistent atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013;14(3):269-275. doi:10.1093/ehjci/jes153.; Faustino A., Providencia R., Barra S., Paiva L., Trigo J., Botelho A. et al. Which method ofleft atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation? Cardiovasc Ultrasound. 2014;12:28. doi:10.1186/1476-7120-12-28.; Ayirala S., Kumar S., O'Sullivan D.M., Silverman D.I. Echocardiographic predictors ofleft atrial appendage thrombus formation. J Am Soc Echocardiogr. 2011;24(5):499-505. doi:10.1016/j.echo.2011.02.010.; Doukky R., Khandelwal A., Garcia-Sayan E., Gage H. External validation of a novel transthoracic echocar-diographic tool in predictingleft atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013;14(9):876-881. doi:10.1093/ehjci/jes313.; Doukky R., Garcia-Sayan E., Gage H., Nagarajan V., Demopoulos A., Cena M. et al. The value of diastolic function parameters in the prediction ofleft atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Cardiovasc Ultrasound. 2014;12:10. doi:10.1186/1476-7120-12-10.; Garcia-Sayan E.D., Patel M., Wassouf M., Pant R., D'Silva O.J., Kehoe R.F., Doukky R. Derivation and validation of E/e ratio as a parameter in the evalu-ation ofleft atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Int J Cardiovasc Imaging. 2016;32(9):1349-1356. doi:10.1007/s10554-016-0916-y.; Doukky R., Garcia-Sayan E., Patel M., Pant R., Wassouf M., Shah S. et al. Impact of diastolic function parameters on the risk forleft atrial appendage thrombus in patients with nonvalvular atrial fibril-lation: a prospective study. J Am Soc Echocardiogr. 2016;29(6):545-553. doi:10.1016/j.echo.2016.01.014.; Sasaki S., Watanabe T., Tamura H., Nishiyama S., Wanezaki M., Sato C. et al. Left atrial strain as evalu-ated by two-dimensional speckle tracking predicts left atrial appendage dysfunction in patients with acute ischemic stroke. BBA Clin. 2014;2:40-47. doi:10.1016/j.bbacli.2014.09.004.; Wang Y., Li M., Zhong L., Ren S., Li H., Tang Y. et al. Left Atrial Strain as Evaluated by Two-Dimensional Speckle Tracking Predicts Left Atrial Appendage Dysfunction in Chinese Patients with Atrial Fibrillation. Cardiology Research and Practice, 2020;2020:1-8. doi:10.1155/2020/5867617.; Piccini J.P., Sievert H., Patel M.R. Left atrial appendage occlusion: rationale, evidence, devices, and patient selection. Eur Heart J. 2017. 21;38(12):869-876. doi:10.1093/eurheartj/ehw330.; Tan N.Y., Yasin O.Z., Sugrue A., Sabbagh A.E., Foley T.A., Asirvatham S.J. Anatomy and Physiologic Roles of the Left Atrial Appendage: Implications for Endocardial and Epicardial Device Closure. Interv Cardiol Clin. 2018;7(2):185-199. doi:10.1016/j.iccl.2017.12.001.; Tilz R.R., Potpara T., Chen J., Dobreanu D., Larsen T.B., Haugaa K.H., Dagres N. Left atrial appendage occlude implantation in Europe: indications and anticoagulation post-implantation. Results of the European Heart Rhythm Association Survey. Europace. 2017;19(10):1737-1742. doi:10.1093/euro-pace/eux254.; Beigel R., Wunderlich N.C., Ho S.Y., Arsanjani R., Siegel R.J. Theleft atrial appendage: anatomy, function, and noninvasive evaluation. JACC Cardiovasc Imaging. 2014;7(12):1251-1265. doi:10.1016/j.jcmg.2014.08.009.; Di Biase L., Santangeli P., Anselmino M., Mohanty P., Salvetti I., Gili S. et al. Does theleft atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol. 2012;60(6):531-538. doi:10.1016/j.jacc.2012.04.032.; Khurram I.M., Dewire J., Mager M., Maqboo F., Zimmerman S.L., Zipunnikov Z. et al. Relationship betweenleft atrial appendage morphology and stroke in patients with atrial fibrillation. Heart Rhythm. 2013;10(12):1843-1849. doi:10.1016/j.hrthm.2013.09.065.; He J., Fu Z., Yang L., Liu W., Tian Y., Liu Q. et al. The predictive value of a concise classification ofleft atrial appendage morphology to thrombosis in non-valvular atrial fibrillation patients. Clin Cardiol. 2020. doi:10.1002/clc.23381.; Wang F., Zhu M., Wang X., Zhang W., Su Y., Lu Y. et al. Predictive value ofleft atrial appendagelobes on left atrial thrombus or spontaneous echo contrast in patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2018;18(1):153. doi:10.1186/s12872-018-0889-y.; Wang Y., Di Biase L., Horton R.P., Nguyen T., Morhanty P., Morhanty P., Natale A. Left Atrial Appendage Studied by Computed Tomography to Help Planning for Appendage Closure Device Placement Journal of Cardiovascular Electrophysiology. 2010;21(9):973-982. doi:10.1111/j.1540-8167.2010.01814.x.; Breitenstein A., Glanzmann M., Falk V., Maisano F., StampfH S.F., Holy E.W. et al. Increased prothrombotic profile in theleft atrial appendage of atrial fibrillation patients. Int J Cardiol. 2015;185:250-255. doi:10.1016/j.ijcard.2015.03.092.; Herrmann M., Whiting M.J., Veillard A.S., Ehnholm C., Sullivan D.R., Keech A.C. Plasma homocysteine and the risk of venous thromboembolism: insights from the FIELD study. Clin Chem Lab Med. 2012;50(12):2213-2219. doi:10.1515/cclm-2012-0078.; Yan Yao, Mei-Sheng Shang, Li-Jian Gao, Jing-Hua Zhao, Xiao-Hui Yang, Tong Liu et al. Elevated homocysteine increases the risk ofleft atrial/left atrial appendage thrombus in non-vaivuiar atrial fibrillation withlow CHA2DS2-VASc score. Europace. 2018;20(7):1093-1098. doi:10.1093/europace/eux189.; Cengel A., Sahinarslan A., Biberoglu G., Hasanoglu A., Tavil Y., Tulmag M., Ozdemir M. Asymmetrical dimethy-largininelevel in atrial fibrillation. Acta Cardiol. 2008;63(1):33-37. doi:10.2143/ac.63.1.2025329.; Chao T.F., Lu T.M., Lin Y.J., Tsao H.-M., Chang S.-L., Lo L.-W. et al. Plasma asymmetric dimethylarginine and adverse events in patients with atrial fibrillation referred for coronary angiogram. PLoS One. 2013;8(8):e71675. doi:10.1371/journal.pone.0071675.; Wei Xia, Yan Wang, Tongqing Duan, Yuanyuan Rong, Yifan Chi, Yibing Shao. Asymmetric dimethylarginine predictsleft atrial appendage thrombus in patients with non-valvular atrial fibrillation. Thromb Res. 2015;136(6):1156-1159. doi:10.1016/j.thromres.2015.10.021.; Ri-Bo Tang, Jian-Zeng Dong, Xian-Liang Yan, Xin Du, Jun-Ping Kang, Jia-Hui Wu et al. Serum uric acid and risk ofleft atrial thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2014;30(11):1415-1421. doi:10.1016/j.cjca.2014.06.009.; Liu F.Z., Liao H.T., Lin W.D., Xue Y.-M., ZhanX.-Z., Fang X.-H. et al. Predictive effect of hyperuricemia onleft atrial stasis in non-valvular atrial fibrillation patients. Int J Cardiol. 2018;258:103-108. doi:10.1016/j.ijcard.2018.01.080.; Ning W., Li Y., Ma C., Qiu L., Yu B. The Refinement of Risk Stratification for Atrial Thrombus or Spontaneous Echo Contrast in Nonvalvular Atrial Fibrillation. Int Heart J. 2017;58(6):885-893. doi:10.1536/ihj.16-444.; Somloi M., Tomcsanyi J., Nagy E., Bodo I., Bexxegh A. D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation. The American Journal of Cardiology. 2003;92(1):85-87. doi:10.1016/s0002-9149(03)00476-4.; Sugiura S., Fujii E., Senga M., Sugiura E., Nakamura M., Ito M. Clinical features of patients withleft atrial thrombus undergoing anticoagulant therapy. J Interv Card Electrophysiol. 2012;34(1):59- 63. doi:10.1007/s10840-011-9633-6.; Pfluecke C., Tarnowski D., Plichta L., Berndt K., Schumacher P., Ulbrich S. et al. Monocyte-platelet aggregates and CD11b expression as markers for thrombogenicity in atrial fibrillation. Clin Res Cardiol. 2016. 105(4):314-322. doi:10.1007/s00392-015-0922-4.; YuYang Chen, Qi Liu, Li Liu, Shu Xiao-Rong, Su Zi-Zhuo, Zhang Hai-Feng et al. Effect of metabolic syndrome on risk stratification forleft atrial orleft atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Chin Med J (Engl). 2016;129(20):2395-2402. doi:10.4103/0366-6999.191744.; Sikorska A., Baran J., Pilichowska-Paszkiet E., Sikora-Frgc M., Krynski T., Piotrowskiet R. et al. Risk ofleft atrial appendage thrombus in patients scheduled for ablation for atrial fibrillation: beyond the CHA2DS2VASc score. Pol Arch Inter Med. 2015;125(12):921-928. doi:10.20452/pamw.3213.; Kapton-Cieslicka A., Budnik M., Gawatko M., Peller M., Gorczyca I., Michalska A. et al. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. Heart. 2019;105(17):1310-1315. doi:10.1136/heartjnl-2018-314492.; Nishikii-Tachibana M., Murakoshi N., Seo Y., Xu D., Yamamoto M., Ishizu T. et al. Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation Prior to Pulmonary Vein Isolation. Am J Cardiol. 2015;116(9):1368-1373. doi:10.1016/j.amjcard.2015.07.055.; Saeed M., Rahman A., Afzal A., Agoston I., Jammula P., Birnbaum Y. et al. Role of transesophageal echocardiography guided cardioversion in patients with atrial fibrillatio, previousleft atrial thrombus and effective anticoagulation. Int J Cardiol. 2006;113(3):401-405. doi:10.1016/j.ijcard.2006.03.036.; Strach K., Meyer C., Hackenbroch M., Tiemann K., Haase J., Pizulli L. et al. Long-term fate ofleft atrial thrombi and incidence of cerebral embolism under continuous anticoagulation therapy. Rofo. 2005;177(12):1706-1712. (In Germ.) doi:10.1055/s-2005-858787.; Bernhardt P., Schmidt H., Hammerstingl C., Hackenbroch M., Sommer T., Luderitz B., Omran H. Fate ofleft atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance Imaging. Am J Cardiol. 2004;94(6):801-804. doi:10.1016/j.amjcard.2004.06.010.; Bernhardt P., Schmidt H., Hammerstingl C., Luderitz B., Omran H. Atrial Thrombi - A Prospective Follow-up Study over 3 Years with Transesophageal Echocardiography and Cranial Magnetic Resonance Imaging. Echocardiography. 2006;23(5):388-394. doi:10.1111/j.1540-8175.2006.00225.x.; Lip G.Y.H., Hammerstingl C., Marin F., Cappato R., Ling Meng I., Kirsch B. et al. Left atrial thrombus resolution in atrial fibrillation or flutter: results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF). Am Heart J. 2016;178:126-134. doi:10.1016/j.ahj.2016.05.007.; Ferner M., Wachtlin D., Konrad T., Deuster O., Meinertz T., von Bardeleben S. et al. Rationale and design of the RE-LATED AF - AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus - Effects of Dabigatran in patients with Atrial Fibrillation. Clin Res Cardiol. 2016;105(1):29-36. doi:10.1007/s00392-015-0883-7.; Hussain A., Katz W.E., Genuardi M.V., Bhonsale A., Jain S.K., Kancharla K. et al. Non-vitamin K oral anticoagulants versus warfarin forleft atrial appendage thrombus resolution in nonvalvular atrial fibrillation or flutter. Pacing Clin Electrophysiol. 2019;42(9):1183-1190. doi:10.1111/pace.13765.; Niku A.D., Shiota T., Siegel R.J., Rader F. Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation. Am J Cardiol. 2019;123(1):63-68. doi:10.1016/j.amjcard.2018.09.027.; Farkowski M.M., Jubele K., Marin F., Gandjbakhch E., Ptaszynski P., Merino J.L. et al. Diagnosis and management ofleft atrial appendage thrombus in patients with atrialfibrillation undergoing cardioversion or percutaneousleft atrial procedures: results of the European Heart Rhythm Association survey. EP Europace. 2020;22(1):162-169. doi:10.1093/euro-pace/euz257.; https://www.aterotromboz.ru/jour/article/view/214

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/214
https://doi.org/10.21518/2307-1109-2020-1-56-70

View record from BASE

4

Academic Journal

THROMBUS OF LEFT ATRIUM AND/OR ITS APPENDAGE IN CASE OF NONVALVULAR ATRIAL FIBRILLATION: FREQUENCY OF DETECTION AND CLINICAL RISK FACTORS ; ТРОМБОЗ ЛЕВОГО ПРЕДСЕРДИЯ И/ИЛИ ЕГО УШКА ПРИ НЕКЛАПАННОЙ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ: ЧАСТОТА ВЫЯВЛЕНИЯ И КЛИНИЧЕСКИЕ ФАКТОРЫ РИСКА

Συγγραφείς: I. A. Zaigrayev, I. S. Yavelov, И. А. Заиграев, И. С. Явелов

Πηγή: Aterotromboz = Atherothrombosis; № 2 (2019); 68-79 ; Атеротромбоз; № 2 (2019); 68-79 ; 2658-5952 ; 2307-1109 ; 10.21518/2307-1109-2019-2

Θεματικοί όροι: предикторы, non-valvular atrial fibrillation, left atrium, left atrial appendage, thrombosis, risk factors, predictors, неклапанная фибрилляция предсердий, левое предсердие, ушко левого предсердия, тромбоз, факторы риска

Περιγραφή αρχείου: application/pdf

Relation: https://www.aterotromboz.ru/jour/article/view/200/229; Kirchhof P., Benussi S., Kotecha D. et. al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC Endorsed by the European Stroke Organization (ESO) fibrillation developed in collaboration with EACTS, 2016. European Heart Journal. 2016;37:2893–2962. doi:10.1093/eurheartj/ehw210.; January C.T., Wann S., Alpert J.S., et al. 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2014;130(23):2071–104. doi:10.1161/CIR.0000000000000041.; Haim M., Hoshen M., Reges O., Rabi Y., Balicer R., Leibowitz M. Prospective national study of the prevalence, incidence, management and outcome of a large contemporary cohort of patients with incident non-valvular atrial fibrillation. J Am Heart Assoc. 2015;4(1):e001486 doi:10.1161 / JAHA.114.001486.; Scherr D., et al. Incidence and predictors of left atrial thrombus prior to catheter ablation of atrial fibrillation 2009. J Cardiovasc Electrophysiol. 2009;20(4):379–84. doi:10.1111/j.1540–8167.2008.01336.x.; Hart R.G., et al. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146(12):857–867. doi:10.7326/0003–4819–146–12–200706190–00007.; Явелов И.С., Окшина Е.Ю. Атеротромботический инсульт при неклапанной фибрилляции предсердий. Неврология, нейропсихиатрия, психосоматика. 2019;11(3S):78–81. doi:10.14412/2074–2711-2019-3S-78–81.; Roldán V., Marín F., Manzano-Fernández S., Gallego P., et al. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2013;62(23):2199–204. doi:10.1016/j.jacc.2013.08.1623.; Hylek E.M., Go A.S., Chang Y., Jensvold N.G., Henault L.E., Selby J.V., Singer D.E. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019–1026. doi:10.1056/NEJMoa022913.; Camm A.J., Kirchhof P., Lip G.Y.H., et al. Guidelines for the management of atrial fibrillation. The Task Force for the Managementof Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12(10):1360–1420. doi:10.1093/europace/euq350.; Ruff C.T., et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383(9921):955–962. doi:10.1016/S0140–6736(13) 62343–0.; Romero J., Cao J.J., Garcia M.J. et al. Cardiac imaging for assessment of left atrial appendage stasis and thrombosis. Nat Rev Cardiol. 2014;11(8):470–480. doi:10.1038/nrcardio.2014.77.; Hwang J.J., Chen J.J., Lin S.C., et аl. Diagnostic accuracy of transesophageal echocardiography for detecting left atrial thrombi in patients with rheumatic heart disease having undergone mitral valve operations. Am J Cardiol. 1993;72(9):67781. doi:10.1016/0002–9149(93) 90884-f.; Doukky R., Khandelwal A., Garcia-Sayan E. et al. External validation of a novel transthoracic echocardiographic tool in predicting left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013;14(9):876–881. doi:10.1093/ehjci/jes313.; Chen J., Zhang H., Zhu D., Wang Y., et al. Cardiac MRI for detecting left atrial/left atrial appendage thrombus in patients with atrial fibrillation Meta-analysis and systematic review. Herz. 2019;44(5):390–397. doi:10.1007/s00059-017-4676–9.; Kitkungvan D., Nabi F., Ghosn M.G., et al. Detection of LA and LAA Thrombus by CMR in Patients Referred for Pulmonary Vein Isolation. JACC: Cardiovasc Imaging. 2016;9(7):809–818. doi:10.1016/j.jcmg.2015.11.029.; Jun Gu, Wei Hu, Xu Liu. The Value of Magnetic Resonance Imaging in Catheter Ablation of Atrial Fibrillation. Clin Cardiol. 2015;38(3):190–194. doi:10.1002/clc.22360.; Frenkel D., D’Amato S.A., Al-Kazaz M., et аl. Prevalence of left atrial thrombus detection by transesophageal echocardiography a comparison of continuous non – vitamin K antagonist oral anticoagulant versus warfarin therapy in patients undergoing catheter ablation for atrial fibrillation. JACC: Clin Electrophysiol. 2016;2(3):295–303. doi:10.1016/j.jacep.2016.01.004.; Malik R., Alyeshmerni D.M., Wang Z., et al. Prevalence and predictors of left atrial thrombus in patients with atrial fibrillation: is transesophageal echocardiography necessary before cardioversion? Cardiovasc Revasc Med. 2015;16(1):12–14. doi:10.1016/j.carrev.2014.12.009.; Yu-Yang Chen, Qi Liu, Li Liu, et al. Effect of metabolic syndrome on risk stratification for left atrial or left atrial appendage thrombus formation in patients with nonvalvular atrial fibrillation. Chin Med J (Engl). 2016;129(20):2395–2402. doi:10.4103/0366–6999.191744.; Anselmino M., Garberoglioa L., Gilia S., et al. Left atrial appendage thrombi relate to easily accessible clinical parameters in patients undergoing atrial fibrillation transcatheter ablation: A multicenter study. Int J Cardiol. 2017;241:218–222. doi:10.1016/j.ijcard.2017.04.014.; Reers S., Agdirlioglu T., Kellner M., et al. Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists. Eur J Med Res. 2016;21(1):41. doi:10.1186/s40001-016-0235–8.; Sugiura E., Nakamura M., Ito M. Clinical features of patients with left atrial thrombus undergoing anticoagulant therapy. J Interv Card Electrophysiol. 2012;34(1):59–63. doi:10.1007/s10840-011-9633–6.; Bernhardt P., Schmidt H., Hammerstingl C., et. аl. Fate of left atrial thrombi in patients with atrial fibrillation determined by transesophageal echocardiography and cerebral magnetic resonance Imaging. Am J Cardiol. 2004;94(6):801–804. doi:10.1016/j.amjcard.2004.06.010.; Bernhardt P., Schmidt H., Hammerstingl C., et. аl. Atrial Thrombi – A Prospective Follow-up Study over 3 Years with Transesophageal Echocardiography and Cranial Magnetic Resonance Imaging. Echocardiography. 2006;23(5):388–394. doi:10.1111/j.1540–8175.2006.00225.x.; Doukky R., Garcia-Saya E., Patel M., et al. Impact of diastolic function parameters on the risk for left atrial appendage thrombus in patients with nonvalvular atrial fibrillation: a prospective study. J Am Soc Echocardiogr. 2016;29(6):545–553. doi:10.1016/j.echo.2016.01.014.; Boyd A.C., McKay T., Nasibi S. et al. Left ventricular mass predicts left atrial appendage thrombus in persistent atrial fibrillation. Eur Heart J Cardiovasc Imaging. 2013;14(3):269–75. doi:10.1093/ehjci/jes153.; Wysokinski W.E., Ammash N., Sobande F., et al. Predicting left atrial thrombi in atrial fibrillation. Am Heart J. 2010;159(4):665–671. doi:10.1016/j.ahj.2009.12.043.; Milhem A., Ingrand P., Tréguer F., et al. Exclusion of Intra-Atrial Thrombus Diagnosis Using D–Dimer Assay Before Catheter Ablation of Atrial Fibrillation. JACC: Clin Electrophysiol. 2019;5(2):223–230. doi:10.1016/j.jacep.2018.09.009.; Ya Suo, Yue Zhang, Yuanyuan Wang, et аl. Reninangiotensin system inhibition is associated with reduced risk of left atrial appendage thrombosis formation in patients with atrial fibrillation. Cardiol J. 2018;25(5):611–620. doi:10.5603/CJ.a2017.0112.; Providкncia R., Fernandes A., Paiva L., Faustino A., et al. Decreased glomerular filtration rate and markers of left atrial stasis in patients with nonvalvular atrial fibrillation. Cardiology. 2013;124(1):3–10. doi:10.1159/000345434.; Sikorska A., Baran J., Pilichowska-Paszkiet E., et al. Risk of left atrial appendage thrombus in patients scheduled for ablation for atrial fibrillation: beyond the CHA2DS2VASc score. Pol Arch Med Wewn. 2015;125(12):921–928. doi:10.20452/pamw.3213.; Kapłon-Cieślicka A., Budnik M., Gawałko M., et al. Atrial fibrillation type and renal dysfunction as important predictors of left atrial thrombus. Heart. 2019;0:1–6. doi:10.1136/heartjnl-2018–314492.; Gunawardene M.A., Dickow J., Schaeffer B.N. et al. Risk stratification of patients with left atrial appendage thrombus prior to catheter ablation of atrial fibrillation: An approach towards an individualizeduse of transesophageal echocardiography. J Cardiovasc Electrophysiol. 2017;28(10):1127–1136. doi:10.1111/jce.13279.; Ochiumi Y., Kagawa E., Kato M., et al. Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unantico-agulated nonvalvular persistent atrial fibrillation. J Arrhythm. 2015;31(5):307–312. doi:10.1016/j.joa.2015.04.002.; Huang J., Wu S.L., Xue Y.M., Fei H.W., Lin Q.W., et al. Association of CHADS2 and CHA2DS2-VASc Scores with Left Atrial Thrombus with Nonvalvular Atrial Fibrillation: A Single Center Based Retrospective Study in a Cohort of 2695 Chinese Subject. Biomed Res Int. 2017;2017:6839589. doi:10.1155/2017/6839589.; Yumei X., Jun H., Shulin W. GW24-e3109 correlation of CHADS2 and CHA2DS2-VASc scores with left atrial thrombus in Chinese patients with nonvalvular atrial fibrillation. Heart. 2013;99: A186. doi:10.1136/heartjnl-2013–304613.519.; Zoppo F., Brandolino G., Berton A. et al. Predictors of left atrium appendage clot detection despite on-target warfarin prevention for atrial fibrillation. J Interv Card Electrophysiol. 2012;35(2):151–158. doi:10.1007/s10840-012-9707–0.; Inoue K., Suna S., Iwakura K., Oka T., Masuda M., et al. Outcomes for atrial fibrillation patients with silent left atrial thrombi detected by transesophageal echocardiography. Am J Cardiol. 2017;120(6):940–946. doi:10.1016/j.amjcard.2017.06.022.; Stoddard M.F., Singh P., Dawn B. et. al. Left atrial thrombus predicts transient ischemic attack in patients with atrial fibrillation. Am Heart J. 2003;145(4):676–682. doi:10.1067/mhj.2003.91.; Kawabata M., Goya M., Sasaki T., Maeda S., et al. Left atrial appendage thrombi formation in Japanese non-valvular atrial fibrillation patients during anticoagulation therapy – Warfarin vs. Direct Oral Anticoagulants. Circ J. 2017;81(5):645–651. doi:10.1253/circj.CJ-16–1089.; Fu Y., Li K., Yang X. ABO blood groups: a risk factor for left atrial and left atrial appendage thrombogenic milieu in patients with non-valvular atrial fibrillation. Thromb Res. 2017;156:45–50. doi:10.1016/j.thromres.2017.05.018.; Yalcin M., Mustafa Aparci, Omer Uz, Zafer Isilak, et al. Neutrophil-Lymphocyte ratio may predict left atrial thrombus in patients with nonvalvular atrial. Clin Appl Thromb Hemost. 2015;21(2):166–171. doi:10.1177/1076029613503398.; Kaya A., Tukkan C., Alper A.T., et al. Increased levels of red cell distribution width is correlated with presence of left atrial stasis in patients with non-valvular atrial fibrillation. North Clin Istanb. 2017;4(1):66–72. doi:10.14744/nci.2017.72324.; Ulua S.M., Akcib O., Ahsena A., et аl. Mean platelet volume, in predicting severity of mitral regurgitation and left atrial appendage thrombosis. Blood Coagul Fibrinolysis. 2014;25(2):119–124. doi:10.1097/MBC.0b013e328364c453.; Providência R., Ferreira M.J., Gonçalves L., et al. Mean corpuscular volume and red cell distribution width as predictors of left atrial stasis in patients with non-valvular atrial fibrillation. Am J Cardiovasc Dis. 2013;3(2):91–102. Available at: https://www.ncbi.nlm.nih.gov/pubmed/23785587/; Pant R., M. Patel, Garcia-Sayan E., et al. Impact of B-type natriuretic peptide level on the risk of left atrial appendage thrombus in patients with nonvalvular atrial fibrillation: a prospective study. Cardiovasc Ultrasound. 2016;(14):4. doi:10.1186/s12947-016-0047–6.; Doukky R., Nagarajan V., Demopoulos A., et al. B-type natriuretic peptide predicts left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Echocardiography. 2013;30(8):889–895. doi:10.1111/echo.12169.; Ochiumi Y., Kagawa E., Kato M., et al. Usefulness of brain natriuretic peptide for predicting left atrial appendage thrombus in patients with unanticoagulated nonvalvular persistent atrial fibrillation. J Arrhythm. 2015;31(5):307–312. doi:10.1016/j.joa.2015.04.002.; Ayirala S., Kumar S., O’Sullivan D.M., et al. Echocardiographic predictors of left atrial appendage thrombus formation. J Am Soc Echocardiogr. 2011;24(5):499–505. doi:10.1016/j.echo.2011.02.010.; Faustino A., Providência R., Barra S., et аl. Which method of left atrium size quantification is the most accurate to recognize thromboembolic risk in patients with non-valvular atrial fibrillation? Cardiovasc Ultrasound. 2014;(12):28. doi:10.1186/1476–7120–12–28.; Yao Y., Shang M.-s., Gao L.-J., et al. Elevated homocysteine increases the risk of left atrial/left atrial appendage thrombus in non-valvular atrial fibrillation with low CHA2DS2-VASc score. Europace. 2018;20(7):1093–1098. doi:10.1093/europace/eux189.; Xia W., Wang Y., Duan T., et al. Asymmetric dimethylarginine predicts left atrial appendage thrombus in patients with non-valvular atrial fibrillation. Thromb Res. 2015;136(6):1156–1159. doi:10.1016/j.thromres.2015.10.021.; Ri-Bo Tang, Jian-Zeng Dong, Xian-Liang Yan, et al. Serum uric acid and risk of left atrial thrombus in patients with nonvalvular atrial fibrillation. Can J Cardiol. 2014;30(11):1415–1421. doi:10.1016/j.cjca.2014.06.009.; Somlói M., Tomcsányi J., Nagy E., et al. D-dimer determination as a screening tool to exclude atrial thrombi in atrial fibrillation. The American Journal of Cardiology. 2003;92:47–49. doi:10.1016/s0002–9149(03) 00476–4.; Sugiura S., Fujii E., Senga M., et al. Clinical features of patients with left atrial thrombus undergoing anticoagulant therapy. Interv Card Electrophysiol. 2012;34:59–63. doi:10.1007/s10840-011-9633–6.; Pfluecke C., Tarnowski D., Plichta L., et аl. Monocyte – platelet aggregates and CD11b expression as markersfor thrombogenicity in atrial fibrillation. Clin Res Cardiol. 2016;105(4):314–322. doi:10.1007/s00392-015-0922–4.; Nishikii-Tachibana M., Murakoshi N., Seo Y., et al. Prevalence and Clinical Determinants of Left Atrial Appendage Thrombus in Patients with Atrial Fibrillation Prior to Pulmonary Vein Isolation. Am J Cardiol. 2015;116(9):1368–1373. doi:10.1016/j.amjcard.2015.07.055.; Wallace T.W., Atwater B.D., Daubert J.P., et аl. Prevalence and Clinical Characteristics Associated With Left Atrial Appendage Thrombus in Fully Anticoagulated Patients Undergoing CatheterDirected Atrial Fibrillation Ablation. J Cardiovasc Electrophysiol. 2010;21(8):849–852. doi:10.1111/j.1540–8167.2010.01729.x.; Cohoon K.P., McBane R.D., et аl. Relationship between body mass index and left atrial appendage thrombus in nonvalvular atrial fibrillation. J Thromb Thrombolysis. 2016;41(4):613–618. doi:10.1007/s11239-015-1266–7.; Kupczynska K., Michalski B.W., Miskowiec D., et al. Association between left atrial function assessed by speckle-tracking echocardiography and the presence of left atrial appendage thrombus in patients with atrial fibrillation. Anatol J Cardiol. 2017;18(1):15–22. doi:10.14744/AnatolJCardiol.2017.7613.; Niku A.D., Shiota T., Siegel R.J., et al. Prevalence and Resolution of Left Atrial Thrombus in Patients With Non-valvular Atrial Fibrillation and Flutter With Oral Anticoagulation. Am J Cardiol. 2019;123(1):63–68. doi:10.1016/j.amjcard.2018.09.027.; Lee W.C., Fang C.Y., Chen Y.L., Fang H.Y., Chen H.C., Liu W.H., Fu M., Chen M.C. Left Atrial or Left Atrial Appendage Thrombus Resolution After Adjustment of Oral Anticoagulant Treatment. J Stroke Cerebrovasc Dis. 2019;28(1):90–96. doi:10.1016/j.jstrokecerebrovasdis.2018.09.015.; Harada M., Koshikawa M., Motoike Y., et al. Left Atrial Appendage Thrombus Prior to Atrial Fibrillation Ablation in the Era of Direct Oral Anticoagulants. Circ J. 2018;82(11):2715–2721. doi:10.1253/circj.CJ-18–0398.; Niku A.D., Shiota T., Siegel R.J. et al. Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation. Am J Cardiol. 2019;123(1):63–68. doi:10.1016/j.amjcard.2018.09.027.; Liu F.Z., Liao H.T., Lin W.D., Xue Y.M., Zhan X.Z., Fang X.H., et al. Predictive effect of hyperuricemia on left atrial stasis in nonvalvular atrial fibrillation patients. Int J Cardiol. 2018;258:103–108. doi:10.1016/j.ijcard.2018.01.080.; https://www.aterotromboz.ru/jour/article/view/200

Διαθεσιμότητα: https://www.aterotromboz.ru/jour/article/view/200
https://doi.org/10.21518/2307-1109-2019-2-68-79

View record from BASE

5

Academic Journal